Skip to main content
. 2016 Nov 4;66(1):91–102. doi: 10.1007/s00262-016-1922-6

Fig. 5.

Fig. 5

Percentage of a PD-1+CD4+ and b PD-1+CD8+ cells at baseline, during and after therapy. Lenalidomide was administered weeks on 1–16 and alemtuzumab weeks 5–16. * p < 0.05, ** p < 0.01, *** p < 0.001